Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution
Abdel Nasser Hosein, … , Udit Verma, Rolf A. Brekken
Abdel Nasser Hosein, … , Udit Verma, Rolf A. Brekken
Published July 23, 2019
Citation Information: JCI Insight. 2019;4(16):e129212. https://doi.org/10.1172/jci.insight.129212.
View: Text | PDF
Research Article Gastroenterology Oncology

Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDA) is a major cause of cancer-related death, with limited therapeutic options available. This highlights the need for improved understanding of the biology of PDA progression, a highly complex and dynamic process, featuring changes in cancer cells and stromal cells. A comprehensive characterization of PDA cancer cell and stromal cell heterogeneity during disease progression is lacking. In this study, we aimed to profile cell populations and understand their phenotypic changes during PDA progression. To that end, we used single-cell RNA–sequencing technology to agnostically profile cell heterogeneity during different stages of PDA progression in genetically engineered mouse models. Our data indicate that an epithelial-mesenchymal transition of cancer cells accompanies tumor progression in addition to distinct populations of macrophages with increasing inflammatory features. We also noted the existence of 3 distinct molecular subtypes of fibroblasts in the normal mouse pancreas, which ultimately gave rise to 2 distinct populations of fibroblasts in advanced PDA, supporting recent reports on intratumor fibroblast heterogeneity. Our data also suggest that cancer cells and fibroblasts may be dynamically regulated by epigenetic mechanisms. This study systematically describes the landscape of cellular heterogeneity during the progression of PDA and has the potential to act as a resource in the development of therapeutic strategies against specific cell populations of the disease.

Authors

Abdel Nasser Hosein, Huocong Huang, Zhaoning Wang, Kamalpreet Parmar, Wenting Du, Jonathan Huang, Anirban Maitra, Eric Olson, Udit Verma, Rolf A. Brekken

×

Figure 6

Analysis of transcriptional activity in different stages of PDA reveals differential epigenetic and transcriptional activity in distinct tissue compartments.

Options: View larger image (or click on image) Download as PowerPoint
Analysis of transcriptional activity in different stages of PDA reveals ...
tSNE plot of number of unique molecular identifiers (nUMIs) in the (A) early and (B) late KIC. (C) Violin plots of epigenetic regulatory genes in the epithelial cell populations of the normal pancreas, early KIC, and late KIC. (D) Violin plots of epigenetic regulator genes in the normal, early fibroblast, and late fibroblast populations showing their upregulation in CAFs. (E) Sequential triple immunohistochemical staining on the same late KIC tumor section for cancer cells (SOX9, shown in pink), mesenchymal cells (vimentin, shown in brown), and increased enhancer activity (BRD4, shown in blue). Well-differentiated ductal epithelium stained solely for SOX9 (green outline). Mesenchymal cancer cells (blue arrows) and CAFs (brown arrows). Original magnification ×10. Inset magnification ×30. (F) Immunohistochemical analysis of human PDA whole tissue sections using the H3K27ac antibody. These representative figures from 2 human PDAs demonstrate the 3+/3+ staining in the stromal fibroblasts (red arrows) with 1+–2+ staining in the cancer epithelium (original magnification, ×20).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts